Gilead strengthens oral immunology pipeline with $1.275 billion deal, while combination prospects depend on early-stage development
Gilead plans to acquire PepStar’s oral IL-23R inhibitor program, adding a piece to its all-oral combination strategy for inflammatory bowel disease. Goldman Sachs acknowledges the long-term strategy, but the lead asset remains in Phase I with no efficacy data publicly disclosed, and the deal will also reduce fourth-quarter earnings per share.
Original source：Goldman SachsFirst published on Unhidea：Original source date：
Key takeaway
Goldman Sachs believes the acquisition will help Gilead expand beyond virology, but realizing its value depends on the early-stage asset’s clinical performance, combination development and commercialization arrangements. It maintains a Neutral rating.
What does $1.275 billion buy?
Gilead has signed a definitive agreement to acquire PepStar’s entire oral IL-23R inhibitor program, including lead asset HCXT-2001 and global rights, for an upfront cash consideration of $1.275 billion, subject to customary closing adjustments. The transaction is expected to close in the fourth quarter of 2026, subject to customary closing conditions.
HCXT-2001 is an oral macrocyclic peptide drug in Phase I development for inflammatory bowel disease and other immune-mediated diseases. It adds a second oral mechanism with a clinically validated target to Gilead’s inflammation and immunology pipeline, expanding options for subsequent monotherapy and combination development.
Why is pairing it with the existing pipeline more strategically significant?
Gilead plans to combine HCXT-2001 with its existing oral α4β7 inhibitor emvistegrast to develop an all-oral combination for inflammatory bowel disease. The strategic link is the complementarity of the two mechanisms, allowing the company to continue expanding treatment options around an existing asset.
Preliminary Phase II data for emvistegrast were disclosed during the week of the report. Goldman Sachs believes the timing of the acquisition reflects growing confidence in the asset and a willingness to continue investing in inflammation and immunology as the company expands beyond virology; emvistegrast is not yet included in Goldman Sachs’ model.
The company also plans to explore HCXT-2001 as a monotherapy for immune-inflammatory diseases outside the gastrointestinal tract. Biologic drugs targeting the IL-23 pathway have already been approved for Crohn’s disease, ulcerative colitis and psoriasis, providing clinical support at the target level for this expansion.
The target is validated, so why does the asset’s value still depend on further development?
HCXT-2001 remains in Phase I, and no efficacy data have been publicly disclosed. Existing biologics validate the IL-23 pathway; the efficacy of the oral candidate itself and its performance in combination with emvistegrast remain central to its development value.
According to the company, internal Phase I data indicate a long half-life that could support once-daily or less frequent dosing. This offers potential differentiation for an oral regimen, but the publicly disclosed advantages currently center on how long the drug remains in the body and the frequency of dosing.
Commercialization capabilities are another constraint. Management previously said it intended to seek an inflammation and immunology partner for emvistegrast because the company lacks the relevant infrastructure; Goldman Sachs is therefore focused on near-term partnership arrangements, development strategy and the path to commercialization.
How are the transaction’s effects reflected in near-term earnings and Goldman Sachs’ valuation?
The company expects the acquisition to reduce both GAAP and non-GAAP earnings per share in the fourth quarter of 2026 by approximately $0.79–0.83. The transaction does not affect financial results for the third quarter of 2026, which are scheduled for release on 29 October.
Goldman Sachs maintains a Neutral rating and a 12-month price target of $142, approximately 9.7% below the 22 October 2026 closing price of $157.19. The target is based entirely on a discounted cash flow model using a perpetual growth rate of 3% and a weighted average cost of capital of 8%; its recognition of the pipeline strategy has not translated into a more positive view of the stock.
